Last reviewed · How we verify
Placebo "30, 50 or 70 mg" — Competitive Intelligence Brief
marketed
Psychiatry/Behavioral Medicine
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo "30, 50 or 70 mg" (Placebo "30, 50 or 70 mg") — Rochester Center for Behavioral Medicine. Placebo produces therapeutic effects through the patient's expectation and belief in treatment, activating endogenous neurobiological pathways independent of pharmacological action.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo "30, 50 or 70 mg" TARGET | Placebo "30, 50 or 70 mg" | Rochester Center for Behavioral Medicine | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo "30, 50 or 70 mg" CI watch — RSS
- Placebo "30, 50 or 70 mg" CI watch — Atom
- Placebo "30, 50 or 70 mg" CI watch — JSON
- Placebo "30, 50 or 70 mg" alone — RSS
Cite this brief
Drug Landscape (2026). Placebo "30, 50 or 70 mg" — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-30-50-or-70-mg. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab